Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, few studies capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different management approaches within universal healthcare systems.
16 June 2016 in Expert Review of Clinical Pharmacology
Background: Cyclosporine and tacrolimus are well established immunosuppressants; however little is known about long term survival rates. The project aim was to compare 10-year graft survival and associated factors among kidney transplant patients within the Brazilian Public Health System (SUS) prescribed either immunosuppressant. Methods: Analyze a national cohort of kidney transplant recipients within SUS. Graft loss defined by death or dialysis for more than three months. Kaplan-Meier method used to estimate cumulative probabilities of survival. Cox proportional hazards model used to evaluate factors associated with progression to graft loss. Results: 13,811 patients were included, 5,887 used cyclosporine and 7,924 tacrolimus. A higher risk of graft loss was associated with tacrolimus, a deceased donor, additional years of age, median period of dialysis greater than 47 months, diagnosis of diabetes as the primary cause of chronic kidney disease and transplantation between 2005 and 2009. Conclusions: Among other factors, tacrolimus-based regimens were associated with worse graft survival.
5 August 2022 in Expert Review of Clinical Immunology
Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day.Efgartigimod is a human IgG1–derived Fc fragment modified at ...
Background: Tuberculosis (TB) remains an important cause of morbidity, the leading cause of death in patients with human immunodeficiency virus (HIV) infection, and a challenge to global public health. This study aimed to analyze the predictors associated with mortality among individuals coinfected with TB/HIV at a reference center in southeastern Brazil. Method: This retrospective cohort study used the data obtained from clinical records and information systems from 2007 to 2014. The data were analyzed using Cox proportional hazards model to identify the independent predictors. Results: Among the 924 individuals studied, 72.7 % were men. The median age was 38 years (range: 16–78 years). The mortality rate was 21.6%. The predictors associated with mortality were as follows: age over 50 years (Adjusted Hazard Ratio [AHR] : 2.52, 95% confidence interval [CI]: 1.39–4.59), CD4+ T lymphocyte count ≤200 cells/mm3 [AHR]: 1.40, 95% [CI]: 0.86–2.27), detectable viral load [AHR]: 1.73, 95% [CI]: 0.98–3.01), and non-use of antiretroviral therapy [AHR]: 2.91, 95% [CI]: 1.71–4.93). Conclusion: Results demonstrated that patients coinfected with TB/HIV have high mortality rates. Therefore, it is necessary to address the social determinants of health to provide every individual an equal opportunity to gain access to healthcare to cope with TB/HIV coinfection. Key words: Tuberculosis/HIV, Mortality, Retrospective cohort, Brazil.
31 December 2020 in Expert Review of Clinical Pharmacology
Introduction: Antipsychotics are widely prescribed for patients with schizophrenia. The Brazilian public health system provides these patients free of charge to patients and it is pertinent to evaluate their benefits. Objective: To evaluate the effectiveness of olanzapine and risperidone in the treatment of patients with schizophrenia in the real-world and assessing risk factors for their discontinuation through a national non-concurrent cohort with 16 years of follow-up. Methods: Three SUS administrative databases were integrated by deterministic-probabilistic linkage. After patients were matched (1:1) for psychiatric hospitalization, year of receiving the antipsychotic, sex, and age, considering either olanzapine or risperidone at study entry. Kaplan-Meier was used to estimate the cumulative probabilities of discontinuation of treatment and associated factors were identified. Sensitivity analyses were performed. Results: 3416 pairs of patients were included. Olanzapine had a longer time until discontinuation of treatment (p = 0.021), and risperidone had a higher risk of discontinuation (p = 0.021). Among patients persistent for at least 24 months, there was no statistically significant difference. Conclusion: Olanzapine demonstrated superior real-world effectiveness over risperidone, in terms of survival and psychiatric hospitalization. This superiority was not sustained in all analyses.
The maintenance of patients with renal transplant typically involves two or more drugs to prevent rejection and prolong graft survival. The calcineurin inhibitors (CNI) are the most commonly recommended medicines in combinations with others. While immunosuppressive treatment regimens are well established, there is insufficient long-term effectiveness data to help guide future management decisions. The study analyzes the effectiveness of treatment regimens containing CNI after renal transplantation during 16 years of follow-up with real-world data from the Brazilian National Health System (SUS). This was a retrospective study of 2318 SUS patients after renal transplantion. Patients were propensity score-matched (1:1) by sex, age, type and year of transplantation. Kaplan–Meier analysis was used to estimate the cumulative probabilities of survival. A Cox proportional hazard model was used to evaluate factors associated with progression to graft loss. Multivariable analysis, adjusted for diabetes mellitus and race/color, showed a greater risk of graft loss for patients using tacrolimus plus mycophenolate compared to patients treated with cyclosporine plus azathioprine. In conclusion, this Brazilian real-world study, with a long follow-up period using matched analysis for relevant clinical features and the representativeness of the sample, demonstrated improved long-term effectiveness for therapeutic regimens containing cyclosporine plus azathioprine. Consequently, we recommend that protocols and clinical guidelines for renal transplantation should consider the cyclosporine plus azathioprine regimen as a potential first line option, along with others.